Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.

Ali Afshar OmeriehUwe HaberkornChristian ZechmannThomas ArmorWalter MierFabian SpohnNils DebusTim Holland-LetzJohn BabichClemens Kratochwil

Published in: European journal of nuclear medicine and molecular imaging (2017)

The first dose of RLT with 131I-MIP-1095 presented with low side effects and could significantly reduce the tumor burden in a majority of patients. The second and third therapies were less effective and presented with more frequent and more intense side effects, especially hematologic toxicities and xerostomia.

Keyphrases

prostate cancer
end stage renal disease
squamous cell carcinoma
newly diagnosed
ejection fraction
small cell lung cancer
chronic kidney disease
peritoneal dialysis
radical prostatectomy
stem cells
cancer therapy
mesenchymal stem cells
pet imaging
risk factors
bone marrow
cell therapy
patient reported